Rain Enhancement Technologies Holdco, Inc. Class A Common Stock

RAIN

Rain Enhancement Technologies Holdco, Inc. Class A (RAIN) is a company focused on developing and commercializing advanced weather modification and enhancement technologies. It aims to leverage innovative solutions to improve rainfall, manage water resources, and address environmental challenges through proprietary platforms and scientific approaches.

$1.55 -0.06 (-3.73%)
đźš« Rain Enhancement Technologies Holdco, Inc. Class A Common Stock does not pay dividends

Company News

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights
GlobeNewswire Inc. • Rain Oncology Inc. • December 13, 2023

NEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (Nasdaq: RAIN) (“Rain”), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. (“Pathos”) will acquire Rain for $1.16 in cash per share plus a non-tradeable contingent value right (a “CVR”) for potential cash payments of up to ap...

3 Top Penny Stocks to Buy According To Insiders In October
PennyStocks • J. Samuel • October 16, 2023

Penny stocks to buy according to insiders. The post 3 Top Penny Stocks to Buy According To Insiders In October appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Rain Oncology And 3 Other Stocks Under $1 Insiders Are Buying
Benzinga • Lisa Levin • October 16, 2023

The Dow Jones closed slightly higher on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions fo...

Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
GlobeNewswire Inc. • Rain Oncology Inc. • October 16, 2023

NEWARK, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) r...

Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire Inc. • Rain Oncology Inc. • August 10, 2023

– Evaluating a number of opportunities to diversify pipeline in precision oncology –

Related Companies